CD40 Generation 2.5 Antisense Oligonucleotide Treatment Attenuates Doxorubicin-induced Nephropathy and Kidney Inflammation

Aaron J Donner, Steve T Yeh, Gene Hung, Mark J Graham, Rosanne M Crooke and Adam E Mullick

Preclinical and clinical data suggest CD40 activation contributes to renal inflammation and injury. We sought to test whether upregulation of CD40 in the kidney is a causative factor of renal pathology and if reduction of renal CD40 expression, using antisense oligonucleotides (ASOs) targeting CD40, would be beneficial in mouse models of glomerular injury and unilateral ureter obstruction. Administration of a Generation 2.5 CD40 ASO reduced CD40 mRNA and protein levels 75–90% in the kidney. CD40 ASO treatment mitigated functional, transcriptional, and pathological endpoints of doxorubicin-induced nephropathy. Experiments using an activating CD40 antibody revealed CD40 is primed in kidneys following doxorubicin injury or unilateral ureter obstruction and CD40 ASO treatment blunted CD40-dependent renal inflammation. Suborgan fractionation and imaging studies demonstrated CD40 in glomeruli before and after doxorubicin administration that becomes highly enriched within interstitial and glomerular foci following CD40 activation. Such foci were also sites of ASO distribution and activity and may be important sites of ASO activity, as CD40 ASO treatment blunted renal inflammation. These studies suggest an important role of interstitial renal and/or glomerular CD40 to augment kidney injury and inflammation and demonstrate that ASO treatment could be an effective therapy in such disorders.

Introduction

Approximately 13% of the US population suffers from chronic kidney disease and the prevalence of this condition is expected to rise.1,2 Glomerulonephritis is a common manifestation of chronic kidney disease and is associated with chronic interstitial inflammation and fibrosis.3 Patients with the most severe manifestations of glomerulonephritis, such as steroid-resistant nephrotic syndrome and recurrent focal segmental glomerulosclerosis (FSGS), are not adequately treated with current therapies and are at high risk for end-stage renal disease.

The CD40-CD40L signaling pathway was initially shown to have a crucial role in lymphocyte-dependent adaptive immunity.4 Since those early findings, an appreciation of this pathway in chronic inflammatory diseases has contributed to a much wider understanding of CD40 biology.5–10 The broad cellular expression of CD40 on nonhematopoietic cells within the kidney like fibroblasts, endothelium, and epithelial cells underscores its role in the regulation of both adaptive and innate immunity in various disease states.11–14

Inhibition of the CD40-CD40L signaling pathway has proven beneficial in multiple rodent models of kidney disease.15–20 Additionally, recent work has demonstrated that patients at risk of recurrent FSGS have high plasma titers of CD40 autoantibodies which produce renal injury in mice.21 These studies suggest that CD40 inhibition would have therapeutic value in the treatment of glomerulonephritis and related renal diseases. Efforts to inhibit CD40-CD40L signaling in patients using antagonistic CD40L antibodies have been stymied by adverse thromboembolic events.22,23 Though an antibody-based approach is still being pursued,24 antisense oligonucleotides (ASOs) represent an alternative therapeutic approach.

Due to their unique pharmacokinetic distribution into organs such as the kidney, a CD40 ASO could provide the specificity to inhibit renal CD40 with minimal inhibitory activity at sites of poor ASO distribution such as lymphocytes. Such a targeting strategy would be essential in treating chronic CD40-dependent inflammatory conditions without compromising adaptive immunity. Additionally, a CD40 ASO would not be predicted to exhibit any adverse, generalized thrombotic effects nor have partial agonistic or lymphocyte-depleting activities, which are still hurdles to overcome with any antibody-based CD40-CD40L inhibitor.

Generation 2.5 antisense molecules represent the most potent and advanced chemical class of ASOs and are comprised of 2′-4′ constrained ethyl (cET) modified bicyclic nucleic acid oligonucleotides flanking a central DNA gap. This modification has previously demonstrated robust kidney activity in rodents and nonhuman primates.25 Herein are studies characterizing the renal inflammatory response to CD40 activation in healthy and injured kidneys and an evaluation of the efficacy of CD40 ASO treatment to protect the kidney against such stimuli. These data demonstrate that the renal cortex is a primary site of CD40 signaling which becomes amplified in injured kidneys. Cortical sites of CD40 activation also proved to be excellent sites for ASO activity, as CD40 ASO treatment blunted renal inflammatory responses to CD40 activation and mitigated kidney injury produced by doxorubicin.

Keywords: antisense, CD40, inflammation, kidney

Received 4 June 2015; accepted 16 October 2015; published online publication 1 December 2015. doi:10.1038/mtna.2015.40
Results

Mouse kidneys display elevated basal CD40 expression, which is highly upregulated within the cortical interstitium following CD40 activation

An organ-wide comparison of CD40 mRNA expression in wild-type C57BL/6 mice demonstrated three- to five-fold greater CD40 protein levels in the kidney relative to the colon, liver, or heart (Figure 1a). Next, an activating anti-CD40 monoclonal antibody (CD40 mAb) was administered intravenously (IV) and CD40-dependent inflammation in the kidneys was evaluated. Twenty-four hours following IV administration of an activating CD40 mAb in wild-type or CD40-deficient mice. Data are normalized to mice not receiving the Ab. Renal cortex and medulla CD40 in situ hybridization (ISH) (c,d) and CCL5 ISH (e) before administration of the CD40 mAb (c) or 24 hours following the CD40 mAb (d,e). Mean ± SEM, n = 4/group, scale bar = 50 μm, *P < 0.05 versus all tissues (a) or versus no Ab control (b).

The feasibility of targeting kidney cortical interstitial cells was evaluated using a Generation 2.5 ASO targeting Malat1. Malat1 is a noncoding nuclear retained RNA that is ubiquitously and highly expressed in the kidney, thereby making it an ideal target to evaluate suborgan ASO activity. Kidneys harvested from mice treated 4 weeks with 100 mg/kg/week Malat1 ASO were evaluated for ASO activity (Malat1 ISH) and distribution (ASO immunohistochemistry (IHC)). Malat1 kidney expression in phosphate buffered saline (PBS)-treated mice (Supplementary Figure S1a) was sharply reduced in mice following Malat1 ASO treatment (Supplementary Figure S1b). In addition to the robust Malat1 ASO activity within tubular epithelial cells, ASO activity and distribution were also observed at sites within the cortical interstitium (arrows in Supplementary Figure S1b,c) and glomerulus.
A CD40 ASO demonstrated potent in vitro inhibition of CD40 and CD40-dependent inflammation

A lead CD40 ASO was identified by in vitro and in vivo screens for activity and tolerability as described in the Materials and Methods. This CD40 ASO was further evaluated under the conditions of “free uptake” (i.e., no lipid transfection and/or electroporation) in thioglycollate-elicited peritoneal macrophages (TG-MΦ) in two different screens (Figure 2). In the first, the CD40 ASO specificity was demonstrated by reduction in CD40 mRNA (Figure 2a) and the lack of changes in lipopolysaccharide (LPS)-dependent, CD40-independent increases in CCL5 (Figure 2b). The second screen used a combination of IFN-γ to prime CD40 followed by administration of the activating CD40 mAb. As shown in Figure 2c,d, CD40 mAb-dependent activation of CD40 resulted in a greater than 20- and 50-fold induction of CD40 and CCL5 mRNA, respectively. In contrast, CD40 ASO treatment reduced the induction of CD40 by up to 90% and attenuated CD40 mAb-dependent induction of CCL5 by up to 75%. CCL5 protein levels in the media were analyzed by enzyme-linked immunosorbent assay (ELISA) at 24 hours and were reduced 80% with CD40 ASO treatment (Figure 2e). The control ASO demonstrated little to no effect in both screens and no effects of the CD40 mAb were observed in TG-MΦ isolated from CD40 knockout mice.

CD40 ASO treatment resulted in robust inhibition of CD40 mRNA and CD40-dependent inflammation in the kidney

The CD40 ASO was subsequently evaluated in models of acute kidney inflammation. CD40 ASO treatments were given SC at 40 mg/kg/week for 4 weeks and kidneys were harvested 4 hours following an IP challenge of 0.5 mg/kg LPS (Figure 3a,b). Previous studies have established maximal kidney CD40 mRNA induction 4 hours following LPS (data not included). As observed in TG-MΦ, CD40 mRNA, but not CCL5 mRNA, was reduced with CD40 ASO treatment and there was no effect with a control ASO. These data add confidence that the CD40 ASO used in these studies did not impact inflammatory pathways unrelated to CD40.

Next, the ability of the CD40 ASO to attenuate CD40-dependent renal inflammation was evaluated in mice given the activating CD40 mAb. Mice received two SC administrations of 40 mg/kg/week ASO (study days 0 and 7) and then they received 25 μg of the activating CD40 mAb (on day 10) by IV. Kidneys were harvested 24 hours after Ab administration. Kidney CD40 protein and mRNA were reduced 80% with CD40 ASO treatment, but were unchanged in mice receiving the control ASO (Figure 3c). The activating CD40 mAb produced large elevations in CD40-dependent inflammation and had no effect in CD40 knockout mice (Figures 1b and 3d). Mice receiving the CD40 ASO also did not display any effect on CD40 expression, it did elevate E Selectin, CCL5, and IL12p40 (IL12/IL23) expression in this one experiment. However, these results were not recapitulated in another study (see below).

A dose–response experiment was performed to further corroborate CD40-dependent ASO activity as well as to determine an optimal dose for pharmacology studies. Mice received 5, 15, or 40 mg/kg of the CD40 ASO or 40 mg/kg of the control ASO on study days 0, 4, and 7. Next, 25 μg
of the CD40 mAb was given on study day 10 and then kidneys were harvested 24 hours afterward. Dose-dependent reductions of CD40 and CD40-dependent inflammation were observed with CD40 ASO treatments with little to no changes observed with control ASO treatment (Supplementary Figure S3a). Interestingly, markers of macrophages (F4/80),
B cells (CD19) and T cells (CD3d) were not altered following acute CD40 activation with the CD40 mAb (Supplementary Figure S3b). These data suggest doses above 15 mg/kg would be expected to produce robust kidney CD40 inhibition. 

**Bone marrow CD40 deficiency resulted in near complete mitigation of CD40-dependent renal inflammation**

To determine the contribution of parenchymal renal cells versus cells of hematopoietic origin, bone marrow transplantation...
was used to create chimeric mice with CD40 deficiency either on bone marrow or non-bone marrow-derived cells. CD40 KO recipient mice received bone marrow (BM) from wild-type (WT) mice (CD40 KO/BM:WT) whereas the WT recipient mice received BM from either WT or CD40 KO animals (WT/BM:WT and WT/BM:CD40 KO, respectively). Mice received two SC administrations of 40 mg/kg/week ASO (study days 0 and 7) and then they received 25 μg of the activating CD40 mAb (on day 10). Kidneys were harvested 24 hours later and mRNA expression of ICAM1, VCAM, E Selectin, CCL5, IL12p40, and CD40 were analyzed (Figure 3f). In the kidneys of WT/BM:WT animals, each of these inflammatory markers were induced by two- to sevenfold following CD40 mAb administration. Relative to WT/BM:WT mice, the induction of CCL5 and IL12p40 were unchanged in CD40 KO/BM:WT mice, but were almost completely abrogated in the WT/BM:CD40 KO mice suggesting myeloid CD40 to be the principal source of CD40-dependent renal cytokine induction. The adhesion molecules ICAM1, VCAM, and E Selectin were induced only 40–50% in CD40 KO/BM:WT mice, but were almost completely abrogated in the WT/BM:CD40 KO mice suggesting myeloid CD40 to be the principal source of CD40-dependent renal cytokine induction. Thus, these data suggest myeloid-CD40 to be the principal cell type that is activated non-BM-derived CD40 to be the principal cell type that is activated.

**CD40 ASO treatment improved renal function and pathology in mice with DOX nephropathy.** To explore the role of CD40 in a model of renal disease, we evaluated CD40 ASO treatment in DOX nephropathy. Exploratory studies characterizing the response to 10.5 mg/kg IV DOX administration revealed large variations in animal health and the severity of nephropathy. Therefore, experiments were performed to identify appropriate biomarkers to minimize cohort response variability. Reductions in body weight and increases in urine NGAL and proteinuria were found to be excellent predictors of DOX nephropathy when assessed 1 week following DOX administration and were used to remove outliers. Mice demonstrating a moderate response to DOX were then randomized into four groups and treated weekly over 8 weeks with PBS, control ASO (25 mg/kg), and high dose (25 mg/kg) CD40 ASO. Treatments were initiated 2 weeks after DOX administration to model a therapeutically relevant treatment regimen as previous studies have demonstrated glomerular hypertrophy and significant CD4+ and CD8+ renal cell infiltrates in this model 2 weeks after DOX administration.26

Dose-responsive reductions of kidney CD40 and improvements in fluorescein isothiocyanate conjugated inulin (FITC-inulin) plasma elimination and proteinuria were observed in mice after receiving 8 weeks of CD40 ASO treatments (Figure 4a–c). It was noteworthy that FITC-inulin plasma elimination in the 25 mg/kg CD40 ASO group approached that measured in healthy mice. Proteinuria was also maximally reduced in the mice receiving 25 mg/kg of the CD40 ASO. Consistent with reductions of CD40 expression and improvements in kidney function, markers of renal injury, inflammation and fibrosis, like CCL5, MCP-1 and NGAL (Figure 4d,e) and CTGF (Supplementary Table S1), were also reduced with CD40 ASO treatment. Kidney periodic acid-Schiff sections revealed marked improvement in DOX-mediated pathology as demonstrated by an improvement of glomerular nephropathy, interstitial and mesangial expansion and granular tubular casts in CD40 ASO-treated mice (Figure 4h,i) versus controls (Figure 4f,g).

It has been demonstrated that T-cells and macrophages have a large influence on disease progression in DOX nephropathy and that CD40L inhibition reduced leukocyte infiltrates.20 Consistent with those reports, CD40 ASO treatment decreased renal T-cell recruitment as assessed both by CD3d mRNA expression and CD3d IHC and CD4 and CD8 mRNA expression.
expression (Supplementary Table S1). Concordant with the reduction in T-cells, IL-2 expression was maximally reduced in the high-dose CD40 ASO group. We did not observe a decrease of renal macrophage content, by CD68 IHC (data not shown) or by mRNA expression (Supplementary Table S1). We then sought to determine whether there was a shift in the balance in M1 versus M2 macrophage lineages. No net change in renal macrophage subtypes were detected as both M1 (IL-12 and TNF-α), as well as M2 (TGF-β and CD206) cytokine mRNAs were similarly induced by DOX and unchanged in the CD40 ASO-treated animals (Supplementary Table S1).

CD40 expression, but not CD40L, is enriched in renal glomeruli and elevated in DOX nephropathy

Previous work had suggested increased CD40 expression in a variety of cell types within the renal cortex following doxorubicin administration. Specifically, early in DOX nephropathy, CD40 appeared elevated on glomerular cells and then becomes more widespread throughout the renal cortex. We evaluated the renal suborgan expression of CD40 mRNA in mice with early stage doxorubicin-induced (DOX) nephropathy and healthy controls. To isolate glomeruli, animals were perfused with a suspension of magnetic beads, kidneys were then mechanically and enzymatically digested and glomeruli were purified from the resulting tissue digest using a magnet. A 10-fold enrichment of the glomerular-specific marker, nephrin, was achieved in glomerular fractions (Figure 5a). Two weeks following DOX administration, whole kidney CD40 and CD40L mRNA expression were increased approximately fourfold (Figure 5b). In both healthy and DOX-injured kidneys, CD40 expression was enriched in glomerular fractions. In contrast, CD40L expression was similar within...
all renal fractions in either healthy or DOX-injured kidneys (Figure 5b). Markers of T cells (CD3d mRNA) and macrophages (CD68 mRNA) were modestly elevated in glomerular fractions; however following DOX injury, large increases in CD68 were also observed in nonglomerular fractions (Figure 5c).

CD40-dependent inflammation was enhanced in DOX nephropathy and attenuated by CD40 antisense oligonucleotide (ASO) treatment

To determine if DOX nephropathy sensitized kidneys to CD40 signaling and whether CD40 ASO treatment could attenuate this effect, the activating CD40 mAb was given to mice with either low or high DOX nephropathy that had also received control or CD40 ASO treatments. As previously described, DOX nephropathy was initiated with a single IV dose of 10.5 mg/kg DOX, but unlike the previous experiment, the low and high DOX injury outliers were studied. At 29, 33, and 36 days following DOX administration, 25 mg/kg control or CD40 ASO treatments were given followed by 25 μg of the CD40 mAb on day 39. Kidneys were harvested 24 hours later.

In PBS-treated mice receiving the CD40 mAb, there were larger increases in kidney CD40 protein and mRNA in the high DOX injury mice relative to low DOX injury mice (Figure 6a). High DOX injury mice also had greater kidney inflammatory responses to the CD40 mAb, demonstrated by an approximately 40- versus 7-fold CCL5 increase in the high and low PBS-treated mice, respectively (Figure 6b). CD40 ASO treatment sharply attenuated or prevented CD40 mAb-dependent inflammatory responses by up to 90%.

Analysis of the distribution of CD40 and CCL5 mRNA expression by ISH revealed a focal distribution pattern in the kidney cortex in DOX nephropathy similar to that observed in healthy mice receiving the activating CD40 mAb. Analysis of successive sections revealed similar, but possibly not identical, sites expressing CD40 and CCL5 within the cortex (Figure 6d).
CD40-dependent inflammation was enhanced in obstructed kidneys and attenuated by CD40 ASO treatment

Unilateral ureter obstruction (UUO) studies were performed to determine the efficacy of CD40 ASO treatment to blunt CD40-dependent inflammation in a renal disease model not driven by glomerular injury. Additionally, since ASOs have been shown to target cortical interstitial cells, ASO treatments given when glomerular filtration rate is restricted should still result in an attenuation of CD40-dependent cortical inflammatory responses. CD40 ASO treatments were given to mice 1, 4, and/or 8 days following UUO using three different dosing paradigms: three administrations of 25 mg/kg (treatments on day 1, 4, and 8; 75 mg/kg total dose) or two administrations of 25 mg/kg (treatments on day 4 and 8; 50 mg/kg total dose) or a single administration of 25 mg/kg (treatment on day 8). Mice were given the CD40 mAb on day 10 and then kidneys were harvested on day 11.

CD40-dependent inflammation was amplified in the obstructed kidney following CD40 mAb administration (Figure 7a). For example, CD40 mAb treatment increased renal CD40, CCL5 and IL-12 by 22-, 116- and 84-fold, respectively, in the obstructed kidney, whereas in the healthy contralateral kidney, CD40, CCL5, and IL12p40 were increased 4–10-fold less. Ureter obstruction resulted in a large increase in renal fibrosis and macrophage infiltration markers (TGFβ1, COL1A1, and F4/80), which were unaffected by either CD40 activation or in CD40 knockout mice (Figure 7b). CD40 ASO treatments mitigated CD40 Ab-dependent induction of inflammation in a dose-dependent manner in both the healthy contralateral and obstructed kidneys (Figure 7c,d). The efficacy of the CD40 ASO treatment in the obstructed kidney was noteworthy given its heightened response to the CD40 Ab. In the obstructed kidneys from either the 50 or 75 mg/kg total dose CD40 ASO groups, CD40, CCL5, and IL12p40 were reduced by 80–85%, which approached that observed in the CD40 knockout mice (Figure 7d). Large increases in cortical interstitial CD40 mRNA expression were observed in the obstructed kidneys following CD40 mAb administration, which were largely eliminated in mice receiving CD40 ASO treatments (Figure 8).

Figure 8 Interstitial CD40 expression was primed for activation in kidneys with ureter obstruction and could be markedly reduced with CD40 antisense oligonucleotide (ASO) treatment. Kidney CD40 in situ hybridization performed in the healthy and obstructed kidneys in UUO mice receiving phosphate buffered saline (PBS) + CD40 mAb or 75 mg/kg CD40 ASO + CD40 mAb. Scale bar = 50 μm.

Discussion

The experiments described herein were conducted to (i) identify renal sites susceptible to CD40 activation, (ii) determine whether antisense inhibition of CD40 could ameliorate disease in a mouse model of glomerular injury, (iii) test the hypothesis that CD40 is primed in kidneys with preexisting injury, and (iv) determine if CD40-dependent renal inflammation could be abrogated with CD40 ASO treatment. Our results demonstrate that CD40 ASO treatment resulted in a 75–90% reduction of renal CD40 across several models of kidney injury. CD40 ASO treatment mitigated functional, transcriptional, and histologic assessments of DOX nephropathy. Moreover, these studies demonstrate that CD40 activation, which is primed at renal cortical sites following kidney injury, results in a myriad of inflammatory responses which can be effectively attenuated with CD40 ASO treatment.

DOX nephropathy models the progressive podocyte depletion, tubulointerstitial inflammation, and the development of glomerulosclerosis similar to the pathogenic changes observed in FSGS. Previous studies have demonstrated that blockade of CD40-CD40L signaling via administration of a CD40L antagonistic antibody was effective at mitigating disease. Our data further support an important role of CD40 in a mouse model of chronic kidney disease and also suggest that renal expression of CD40 has an important role to promote inflammation and disease. Studies have demonstrated enhanced renal CD40 in renal biopsy samples following allograft rejection, recurrent FSGS, and in lupus nephritis.
Collectively, these data suggest therapeutic inhibition of renal CD40 could provide benefit in patients with kidney inflammation or glomerulonephritis.

To our knowledge, this is the first demonstration that CD40 activation results in an induction of a diverse set of inflammatory mediators such as adhesion molecules, cytokines, and chemokines within the kidney and that these responses are amplified with pre-existing injury. The pattern of CD40 induction within the cortical interstitium was similar in healthy, DOX injured, and obstructed kidneys, although the intensity of CD40 expression was highest in the obstructed kidney. Previous studies have suggested a role of CD40 signaling in the cortical inflammatory responses to DOX-induced injury. Additional studies have shown that renal tissue exhibits high basal CD40 vascular expression that is subject to a greater level of induction following LPS compared to vascular CD40 expression that is subject to a greater level of induction following LPS compared to vascular CD40 expression in the heart, lungs, small intestine, and brain. We also observed that basal CD40 expression was more abundant in the kidney compared to the colon, liver, or heart, and can be increased by up to 20-fold following CD40 activation.

The putative sites of renal CD40 activation may be glomerular cells, interstitial fibroblasts, endothelial cells, dendritic cells, macrophages, or other immune cell infiltrates. Previous work demonstrated strong upregulation of CD40 in glomerular cells 2 weeks after DOX nephropathy induction followed by loss of glomerular expression and increased expression in proximal tubular epithelium (PTEC) and cortical interstitium. Histological studies have demonstrated a rich network of fibroblasts and dendritic cells within the renal interstitium that would be predicted to be highly responsive to CD40 activation. In vitro studies have demonstrated that endothelial responses to CD40 activation results in a broad and profound stress response resulting in activation of diverse inflammatory and thrombotic pathways.

Despite this wealth of knowledge of CD40 expression, the contribution of these cell types to CD40 signaling that underlies renal disease is still unclear. Our data demonstrates low basal CD40 expression within glomeruli and tubular epithelial cells which during disease states becomes highly enriched within glomeruli and cortical interstitial sites. Interestingly, the particular disease state (e.g., DOX nephropathy or UUO) did not make for qualitative differences in the distribution of renal CD40 expression, nor did the administration of the activating CD40 mAb. Importantly, we show that activation of renal CD40 using the CD40 mAb is mostly dependent on a myeloid-derived cell population, as bone marrow CD40 deficiency results in almost complete attenuation of CD40-dependent renal inflammation. These data do not illuminate the precise cell type mediating these effects, but do suggest a kidney-resident, but myeloid-derived, cell as the CD40 mAb did not result in increased renal macrophages, T cells or B cells. Future studies are needed to determine the relative contributions of myeloid (e.g., CD11c+ DCs and CD11b+ macrophages) and non-myeloid cell-specific CD40 activity in the context of renal inflammation and disease. Additionally, studies are also needed to clarify the dependency of CD40L in the context of CD40 inhibition, as reports have established non-canonical pathways of CD40L signaling that do not involve CD40 (refs. 33–36). Finally, studies to precisely determine the relative potency of ASOs across unique cell populations that reside in the renal cortex during disease will be an important advance in defining the therapeutic potential of the Generation 2.5 chemistry platform for chronic kidney disease.

The robust potency of CD40 ASO to mitigate CD40 Ab-induced renal inflammation was striking. Although it is well established that the renal cortex, specifically the PTEC, is the site with the greatest concentration of ASO, few studies have investigated the distribution and activity of ASOs at non-PTEC sites within the renal cortex. Additionally, the activity of Generation 2.5 ASOs, which represent the most potent and advanced class of ASOs, have only begun to be characterized in the kidney. In a recent report, Hung et al. demonstrated 93% target inhibition in the kidney with a cEt ASO targeting Malat1, which was improved compared to the 72% target inhibition observed with the generation 2.0 MOE gapmer Malat1 ASO. Here we demonstrate that cells, myeloid-derived and possibly endothelial cells, in the renal cortex, distinct from the PTECs, can be effectively targeted with Generation 2.5 ASOs.

Experiments in the UUO model support the concept that CD40 is primed and can be activated within the interstitium, but not the glomerulus or tubular epithelium, as the ASO treatments and the CD40 mAb were given after ureter obstruction when there is severely restricted or absent glomerular filtration rate. For example, a single dose of the CD40 ASO at 25mg/kg given 8 days after ureter obstruction resulted in an attenuation of CD40 and the CD40-dependent inflammatory markers CCL5 and IL12p40 (Figure 7d). These data suggest that renal cortical ASO distribution is not primarily dependent upon glomerular filtration and reabsorption processes, but can occur via a tubular-independent renovascular ASO distribution pathway. Such data raises the prospect that in patients with reduced glomerular filtration rate might still be benefit from CD40 ASO therapy.

In summary, antisense inhibition of CD40 in established DOX nephropathy mitigated functional, transcriptional, and pathological assessments of disease severity and sharply attenuated CD40-dependent inflammatory responses in the kidney. The ability of CD40 ASO treatment to sharply attenuate or prevent CD40-dependent renal inflammation in multiple models of kidney injury highlights the potential of antisense therapy to treat such CD40-dependent inflammatory states. This could prove beneficial in patients with aberrant or excessive renal CD40 activation. The source of such activation could be similar to that modeled in these studies with the CD40 activating Ab, as would be the case in patients with high titers of autoantibodies to CD40 (ref. 21). Additionally, activated T cells and platelets are a rich source of CD40L and sCD40L, respectively, which could act as triggers for CD40-dependent renal inflammation. Identifying patients with such aberrant CD40 signaling would be important in selecting patient subpopulations that could maximally benefit from a CD40 ASO therapeutic.

Materials and methods

**CD40 ASO lead determination.** Antisense phosphorothioate oligonucleotides (ASOs) with 5'-methyl cytosine and containing 2'-O-methoxyl (MOE, e) and 2-O,4-C-((S)-ethylidene)-D-ribose (cEt, k) modified sugars
were synthesized at Isis Pharmaceuticals (Carlsbad, CA) as described previously.40 Chimeric ASOs containing both Generation 2.0 (i.e., MOE) and Generation 2.5 (i.e., cET) chemistries 16 bases in length had the modified sugar pattern, eek-10-kke, wherein the three terminal 5' and 3' nucleotides contain modified sugars that flank 10 nucleotides with unmodified sugars were screened for activity and tolerability. Extensive in vitro activity screens were performed followed by in vivo tolerability and activity studies to identify a lead CD40 ASO. Additional SAR was performed around this sequence to identify an active and well tolerated lead (CD40 ASO) containing a kkk-10-kkk sugar composition and with nucleotide sequence CAGATTTATTTAGCCA. A control ASO of the same chemical class as CD40 ASO, but not hybridizing to any known murine RNA sequences, was used and had the following nucleotide sequence, GGCCAATACGCC GTCA. The Malat1 (NCBI Accession NR_002847) ASO with kkk-10-kkk sugar composition had the following nucleotide sequence, CTAGTTCACTGAATGC.

In vitro CD40 ASO activity. In vitro CD40 activity of ASOs was tested in two screens using thioglycollate-elicited peritoneal macrophage (TG-Mφ) treated with 10 μmol/l ASO for 1 hour in media (10% fetal bovine serum, 1× antibiotic/antimycotic Dulbecco’s Modified Eagle’s Medium), washed with PBS, and the media replaced before activating the cells (Supplementary Figure S1). In the first screen, 0.5 μg/ml LPS was added and the cells were harvested at 4, 12, and 24 hours. In the second screen, CD40 was activated by 100 ng/ml IFN-γ (R&D Systems, Minneapolis, MN) for 4 hours followed by 10 μg/ml activating anti-CD40 monoclonal antibody (mAb), clone 3/23 (Abcam, Cambridge, MA) for 4, 15, or 24 hours. Media was collected to measure CCL5 protein levels and the cells were lysed for mRNA expression analysis.

Animal studies. All animal procedures were reviewed and approved by the Isis Institutional Animal Care and Use Committee and conducted in conformity with the Public Health Service Policy on Humane Care and Use of Laboratory Animals. All mice were housed in a pathogen-free environment and given food and water ad libitum. Male wild-type C57BL/6 (WT) (JAX #000664) and CD40 knockout (CD40 KO) (JAX #002928) mice were used for studies not utilizing DOX. Male BALB/c mice (Charles River, San Diego, CA) were used for DOX studies. CD40 and a control ASO were SC injected once weekly unless otherwise specified at doses ranging from 5 to 100 mg/kg. ASO dosing solutions were prepared in sterile PBS and given at a dose volume of 10 ml/kg body weight.

In vivo tolerability of the lead CD40 ASO was assessed in male inflammation-naive C57BL/6 mice after 4 weeks of SC administration of 50 and 100 mg/kg/week for a combined ASO dose of 200 or 400 mg/kg, respectively. As shown in Supplementary Figure S2, body weight changes, plasma total bilirubin and BUN were unchanged in mice receiving up to 100 mg/kg/week. At 100 mg/kg/week, there were perturbations in spleen size and plasma ALT, which were not observed in the 50 mg/kg/week dose group. Additionally, there were no improvements in activity with dosing beyond 50 mg/kg/week. Therefore, our renal pharmacology studies were performed using doses less than 50 mg/kg/week.

LPS (055:B5, Sigma) and the activating CD40 mAb (clone 3/23, Abcam) were administered IP and IV, respectively. Anesthetized mice were euthanized by cervical dislocation and blood was collected by cardiac puncture and kidneys harvested and cut in half, in the transverse plane, for mRNA expression analysis, protein analysis, and histology.

Bone marrow transplantation. Male WT and CD40 KO mice were irradiated with 7 Gy and then given IV ~400,000 BM donor cells. Six weeks following the bone marrow transplantation, reconstitution was confirmed by measurement of CD40 mRNA expression in peripheral blood leukocyte population (Supplementary Figure S4).

Glomerular isolation. Isolation of glomeruli was performed by the method described by Takemoto et al.41 Briefly, magnetic 4.5 μm Dynabeads (ThermoFisher, Waltham, MA) were perfused at animal sacrifice via the left ventricle. Kidneys were harvested and digested in a collagenase- (Worthington Biochemical Corporation, Lakewood, NJ), hyaluronidase- (Sigma-Aldrich, St. Louis, MO) and DNase- (ThermoFisher) containing buffer. After mechanical disruption, tissue was centrifuged and the pellet was washed. Glomeruli containing Dynabeads were collected by a magnetic particle concentrator.

Renal function assessment. An estimate of renal function was determined by measuring the elimination of plasma FITC-Inulin using a modified version of the FITC-Inulin clearance method.42 Briefly, 8 μl/g body weight of 2.5% FITC-Inulin was given IV and blood was collected 2 hours afterward. Proteinuria was assessed by determining the ratio of urinary albumin and creatinine (ELISA, Kamiya Biomedical, Seattle, WA and Olympus AU400 Clinical Analyzer respectively).

RNA purification and quantitative reverse transcription polymerase chain reaction (qRT-PCR). TG-Mφ or tissues were homogenized and RNA prepared using the PureLink Pro 96 RNA kit (ThermoFisher). mRNA levels were measured using the One-Step RT-PCR kit, gene-specific TaqMan probe and primer sets and the StepOne Plus (ThermoFisher). Sequence information for probe and primer sets can be found in Supplementary Table S2. mRNA levels for target genes were normalized to either total RNA (Ribogreen) or GAPDH mRNA expression.

ELISA. ELISAs were performed for CCL5 (eBioscience, San Diego, CA and R&D Systems), CD40 (R&D Systems), and urinary albumin (Kamiya Biomedical) according to the manufacturer’s instructions. Kidney homogenates were prepared for ELISA by homogenization in RIPA lysis buffer (ThermoFisher) containing buffer. After mechanical disruption, tissue was centrifuged and the pellet was washed. Glomeruli containing Dynabeads were collected by a magnetic particle concentrator.

Histology. Kidneys were fixed in 10% neutral buffered formalin, dehydrated in graded ethanol and embedded in paraffin, sectioned and stained using hematoxylin and eosin or periodic acid-Schiff. IHC was performed using antibodies against CD3d (Serotec, Raleigh, NC) and CD68 (Boster Biologics, Pleasanton, CA) and ASO (generated in-house). CD40, CCL5, or Malat1 mRNA expression was detected via.
ISH using the QuantiGene ViewRNA tissue assay (Affymetrix Santa Clara, CA) according to the manufacturer’s instructions and probes. No probe controls or tissue from CD40 knockout mice were used for negative controls.

Statistics. Data are reported as means ± SEM. Two-tailed Student’s t-test was used for comparisons between two groups. One-way analysis of variance and the Holm-Sidak post hoc test (SigmaStat, Systat Software San Jose, CA) used to determine significance relative to the PBS vehicle control for studies with more than two groups. Statistical significance was considered when P < 0.05.

Supplementary material

Figure S1. Malat1 ASO activity (ISH) and distribution (IHC) in the kidney.

Figure S2. Tolerability and activity evaluation of the lead CD40 ASO in inflammation-naive mice.

Figure S3. Dose responsive reduction of CD40-dependent inflammation with CD40 ASO treatments and leucocyte mRNA marker expression following CD40 mAb administration.

Figure S4. CD40 mRNA expression in blood PBMC cells 6 weeks post BMT.

Table S1. CD40 ASO treatment effects on kidney T cell and macrophage markers in DOX nephropathy.

Table S2. Primer and probe sequences used for qRT-PCR.

Acknowledgments. The authors thank the members of the Histology Core, Yuhong Jiang, Bea DeBrosse-Serra, and Xiaokun Xiao, for their exemplary work in these studies. The authors are also grateful to Chenguang Zhao, Chris May, and Karen He for their energy and enthusiasm as a summer intern. This work was supported by Isis Pharmaceuticals, Inc. All authors are employees of Isis Pharmaceuticals, Inc. All authors are employees of Isis Pharmaceuticals, Inc.

References

1. Coren, J, Selvin, E, Stevens, LA, Manzi, J, Kusek, JW, Egerer, P et al. (2007). Prevalence of chronic kidney disease in the United States. Jama 298: 2038–2047.

2. Moll, S, Meier, M, Formentini, I, Pomposiello, S and Prunotto, M (2014). New renal drug development to face chronic renal disease. Expert Opin Drug Discov 9: 1471–1485.

3. Bohle, A, Mackensen-Haen, S, von Gise, H, Grund, KE, Wehrmann, M, Batz, C et al. (1990). The consequences of tubulo-intestinal changes for renal function in glomerulopathies. A morphometric and cytological analysis. Pathol Res Pract 186: 135–144.

4. Grewal, IS and Flavell, RA (1997). The CD40 ligand. At the center of the immune universe?

5. Kato, K, Santana-Sahagun, E, Rasenti, LZ, Weisihn, MH, Tamura, N, Kobayashi, S et al. (1999). The soluble CD40 ligand (CD154) in systemic lupus erythematosus. J Clin Invest 104: 947–955.

6. Mach, F (1998). Reduction of atherosclerosis in mice by inhibition of CD40 signaling. Nature 394: 200–203.

7. Heesch, C, Dimmeler, S, Hinterzitter, G, van der Brand, MJ, Boersma, E, Zeiher, AM et al. (2003). Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348: 1104–1111.

8. Criswell, LA (2010). Gene discovery in rheumatoid arthritis highlights the CD40/NF-κB signaling pathway in disease pathogenesis. Immunol Rev 233: 55–61.

9. Suttles, J and Stout, RD (2009). Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis. Semin Immunol 21: 257–264.

10. Danese, S, Sans, M and Fiocchi, C (2004). The CD40/CD40L costimulatory pathway in inflammatory bowel disease. Gastroenterology 127: 1035–1043.
37. Geary, RS (2009). Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 5:381–391.

38. Seth, PP, Skwowski, A, Allerson, CR, Vasquez, G, Lee, S, Prakash, TP et al. (2009). Short antisense oligonucleotides with novel 2'-4' conformationally restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem 52:10–13.

39. Harris, RH and Gill, JM (1981). Changes in glomerular filtration rate during complete ureteral obstruction in rats. Kidney Int 19:603–608.

40. Seth, PP, Skwowski, A, Allerson, CR, Vasquez, G, Lee, S, Prakash, TP et al. (2008). Design, synthesis and evaluation of constrained methoxyethyl (cMOE) and constrained ethyl (cEt) nucleoside analogs. Nucleic Acids Symposium Series 52:553–554.

41. Takemoto, M, Asker, N, Gerhardt, H, Lundkvist, A, Johansson, BR, Saito, Y et al. (2002). A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol 161:799–805.

42. Qi, Z, Whitt, I, Mehta, A, Jin, J, Zhao, M, Harris, RC et al. (2004). Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol 286:F580–F596.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Supplementary Information accompanies this paper on the Molecular Therapy–Nucleic Acids website (http://www.nature.com/mtna)